Efficacy and safety of endoscopic submucosal dissection for superficial cancer of the cervical esophagus

Abstract

Background and study aims Cervical esophageal cancer (CEC) is a less common form of cancer and often locally advanced at the time of diagnosis; thus, survival rates for patients with CEC remain poor. However, no reports exist on results of endoscopic submucosal dissection (ESD) for superficial cancer at the cervical esophagus. The aim of this retrospective study was to elucidate the clinicopathological features and clinical outcomes of ESD for superficial CEC.

Patients and methods ESD was performed on 891 lesions (in 662 patients) for superficial esophageal cancer from January 2008 to December 2015. Of these, 45 lesions (45 patients) were enrolled in the case group (CEC), and 405 lesions (375 patients) were enrolled in the control group (superficial cancer in the middle thoracic esophagus). The safety of ESD, including R0 resection rate and adverse events, and the efficacy, such as the local recurrence rate and overall survival rate, were evaluated.

Results The R0 resection rate was 91.1 % in the case group and 96 % in the control group. The rate of esophageal stricture was significantly higher in the case group (20 %) than in the control group (6.6 %). There was no local recurrence, and the 3-year survival rate was 88.4 % in the case group and 96.7 % in the control group.

Conclusions ESD for superficial cancer in the cervical esophagus was achieved safely, and successful local control was also confirmed. However, the esophageal stricture after ESD was more frequent.

• References

• 1 Lee DJ, Harris A, Gillette A. et al. Carcinoma of the cervical esophagus: diagnosis, management, and results. South Med J 1984; 77: 1365-1367
• 2 Grass GD, Cooper SL, Armeson K. et al. Cervical esophageal cancer: a population-based study. Head Neck 2015; 37: 808-814
• 3 Mendenhall WM, Sombeck MD, Parsons JT. et al. Management of cervical esophageal carcinoma. Semin Radiat Oncol 1994; 4: 179-191
• 4 Tepper J, Krasna MJ, Niedzwiecki D. et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008; 26: 1086-1092
• 5 Daiko H, Hayashi R, Saikawa M. et al. Surgical management of carcinoma of the cervical esophagus. J Surg Oncol 2007; 96: 166-172
• 6 Shuangba H, Jingwu S, Yinfeng W. et al. Complication following gastric pull-up reconstruction for advanced hypopharyngeal or cervical esophageal carcinoma: a 20-year review in a Chinese institute. Am J Otolaryngol 2011; 32: 275-278
• 7 Hoebena A, Polak J, Van De Voorde L. Cervical esophageal cancer: a gap in cancer knowledge. Ann Oncol 2016; 27: 1664-1674
• 8 Hanaoka N, Ishihara R, Takeuchi Y. et al. Intralesional steroid injection to prevent stricture after endoscopic submucosal dissection for esophageal cancer: a controlled prospective study. Endoscopy 2012; 44: 1007-1011
• 9 Yamaguchi N, Isomoto H, Nakayama T. et al. Usefulness of oral prednisolone in the treatment of esophageal stricture after endoscopic submucosal dissection for superficial esophageal squamous cell carcinoma. Gastrointest Endosc 2011; 73: 1115-1121
• 10 Saeki H, Tsutsumi S, Yukaya T. et al. Clinicopathological Features of Cervical Esophageal Cancer: Retrospective Analysis of 63 Consecutive Patients Who Underwent Surgical Resection. Ann Surg 2017; 265: 130-136
• 11 Grass GD, Cooper SL, Armeson K. et al. Cervical esophageal cancer: a population-based study. Head Neck 2015; 37: 808-814
• 12 Tachimori Y, Ozawa S, Numasaki H. et al. Comprehensive Registry of Esophageal Cancer in Japan, 2009. Esophagus 2016; 13: 110-137
• 13 Iizuka T, Kikuchi D, Hoteya S. et al. Endoscopic submucosal dissection for treatment of mesopharyngeal and hypopharyngeal carcinomas. Endoscopy 2009; 41: 113-117